ZS ASSOCIATES AS

Their core work

ZS Associates AS operates as Intomics (intomics.com), a Danish computational biology SME specializing in multi-omics data integration and systems biology. They apply network analysis, mathematical modeling, and integrative analysis of transcriptomic, epigenomic, and metabolomic data to understand complex diseases. In practice, they serve as the analytical engine in research consortia — turning large-scale biological datasets into interpretable disease models and biomarker candidates. Their work bridges wet-lab experimental data with computational insights, making them a specialist contributor rather than an experimental lab.

What they specialise in

How they've shifted over time

From 2016 to 2019, their focus was squarely on metabolic disease: type 2 diabetes, pancreatic beta cell function, and multi-omics integration to identify disease risk and treatment targets. By 2021, they had pivoted entirely to oncology — specifically the mechanisms driving cancer metastasis, tumor dormancy, and stromal microenvironment interactions. The shift is a clean transition from one complex disease domain to another, suggesting the underlying competency (multi-omics, systems biology) is stable while the biological application area is evolving toward cancer research.

They are moving deeper into oncology, and a future collaboration offer in cancer genomics, tumor microenvironment modeling, or liquid biopsy biomarker analysis would align well with their current trajectory.

How they like to work

Intomics joins consortia as a specialist contributor — they have never coordinated an H2020 project, always participating. With 25 unique partners across 11 countries in only 2 projects, they operate inside large, diverse consortia rather than small bilateral arrangements. This suggests they are brought in for a defined computational role, likely data analysis and systems modeling, rather than as a generalist research partner.

They have built connections with 25 distinct partners across 11 countries through just two projects, indicating that each consortium was large and internationally diverse. No repeated partners are detectable with only two projects, so geographic loyalty patterns cannot be assessed.

What sets them apart

Intomics is one of very few commercial SMEs in Denmark offering multi-omics data integration as a core business competency rather than a research sideline — they combine academic-grade bioinformatics with a commercial delivery model. Their track record spanning two distinct disease areas (metabolic and oncological) demonstrates that their platform is disease-agnostic, which makes them unusually flexible as a consortium partner. For project coordinators, they offer a rare combination: computational depth without the overhead of a university lab.

Highlights from their portfolio

• T2DSystems
  Their largest project by funding (€471K), combining five omics layers to build a systems-level model of type 2 diabetes — an unusually comprehensive multi-omics integration challenge for an SME.
• Evomet
  An MSCA Innovative Training Network focused on cancer metastasis evolution, signaling a strategic move into oncology and a broader role in training the next generation of computational cancer researchers.